FAAP100

Summary

FAAP100 (FA core complex associated protein 100, HGNC:26171) is a protein-coding gene on chromosome 17q25.3, encoding Fanconi anemia core complex-associated protein 100 (Q0VG06). Plays a role in Fanconi anemia-associated DNA damage response network. It is a selective cancer dependency (DepMap: 14.3% of cell lines).

FAAP100 is a component of the Fanconi anemia (FA; MIM 277650) core complex and is required for core complex stability and FANCD2 (see MIM 227646) monoubiquitination (Ling et al., 2007 [PubMed 17396147]).

Source: NCBI Gene 80233 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 177 total — 3 pathogenic, 1 likely-pathogenic
• Phenotypes (HPO): 159
• Cancer dependency (DepMap): dependent in 14.3% of screened cell lines
• MANE Select transcript: NM_025161

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26171
Approved symbol	FAAP100
Name	FA core complex associated protein 100
Location	17q25.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ22175
Ensembl gene	ENSG00000185504
Ensembl biotype	protein_coding
OMIM	611301
Entrez	80233

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 9 protein_coding, 2 nonsense_mediated_decay

ENST00000327787, ENST00000425898, ENST00000443656, ENST00000536161, ENST00000541246, ENST00000544302, ENST00000545865, ENST00000899631, ENST00000899632, ENST00000959821, ENST00000959822

RefSeq mRNA: 1 — MANE Select: NM_025161 NM_025161

CCDS: CCDS32765

Canonical transcript exons

ENST00000327787 — 9 exons

Exon	Start	End
ENSE00002302091	81552166	81552353
ENSE00003483734	81550248	81551203
ENSE00003492534	81539891	81540950
ENSE00003518046	81549206	81549362
ENSE00003522275	81546909	81547678
ENSE00003555053	81545746	81545882
ENSE00003598336	81541309	81541395
ENSE00003656053	81544004	81544120
ENSE00003667995	81551928	81552052

Expression profiles

Bgee: expression breadth ubiquitous, 199 present calls, max score 92.82.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 18.9533 / max 166.7885, expressed in 1798 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
168758	12.7797	1781
168759	4.3447	1680
168760	1.7572	782
168757	0.0717	25

Top tissues by expression

264 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right hemisphere of cerebellum	UBERON:0014890	92.82	gold quality
cerebellar hemisphere	UBERON:0002245	92.42	gold quality
cerebellar cortex	UBERON:0002129	92.29	gold quality
apex of heart	UBERON:0002098	90.63	gold quality
granulocyte	CL:0000094	90.32	gold quality
cerebellum	UBERON:0002037	90.12	gold quality
spleen	UBERON:0002106	88.99	gold quality
right lobe of thyroid gland	UBERON:0001119	88.81	gold quality
body of pancreas	UBERON:0001150	88.60	gold quality
metanephros cortex	UBERON:0010533	88.33	gold quality
cortical plate	UBERON:0005343	88.29	gold quality
left lobe of thyroid gland	UBERON:0001120	87.88	gold quality
left uterine tube	UBERON:0001303	87.82	gold quality
right uterine tube	UBERON:0001302	87.65	gold quality
right ovary	UBERON:0002118	86.80	gold quality
right lobe of liver	UBERON:0001114	86.68	gold quality
thyroid gland	UBERON:0002046	86.59	gold quality
lower esophagus mucosa	UBERON:0035834	86.58	gold quality
body of uterus	UBERON:0009853	86.40	gold quality
small intestine Peyer’s patch	UBERON:0003454	86.21	gold quality
adenohypophysis	UBERON:0002196	86.12	gold quality
left ovary	UBERON:0002119	85.88	gold quality
body of stomach	UBERON:0001161	85.80	gold quality
endocervix	UBERON:0000458	85.78	gold quality
right coronary artery	UBERON:0001625	85.73	gold quality
ascending aorta	UBERON:0001496	85.71	gold quality
thoracic aorta	UBERON:0001515	85.71	gold quality
mucosa of transverse colon	UBERON:0004991	85.66	gold quality
ectocervix	UBERON:0012249	85.65	gold quality
stromal cell of endometrium	CL:0002255	85.61	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.55

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

23 targeting FAAP100, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-4745-5P	99.98	65.95	1028
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-218-5P	99.93	72.22	2103
HSA-MIR-4302	99.89	67.94	1187
HSA-MIR-3681-3P	99.88	70.46	2254
HSA-MIR-3065-3P	99.87	70.25	1407
HSA-MIR-4319	99.76	69.83	2586
HSA-MIR-4530	99.69	66.47	1509
HSA-MIR-2113	99.58	71.22	1521
HSA-MIR-542-3P	99.34	67.58	1270
HSA-MIR-4733-3P	98.35	65.20	994
HSA-MIR-634	97.74	67.11	818
HSA-MIR-1226-3P	97.51	66.32	1063
HSA-MIR-663B	97.40	62.91	664
HSA-MIR-6772-3P	97.04	65.89	784
HSA-MIR-1291	96.28	65.89	1224
HSA-MIR-6775-3P	95.76	65.91	982
HSA-MIR-7976	95.75	65.67	1186
HSA-MIR-6851-3P	95.73	65.11	688
HSA-MIR-1204	89.50	65.56	109

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 14.3% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 1)

• FAAP100 as a new critical component of the FA-BRCA DNA damage response network. (PMID:17396147)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	faap100	ENSDARG00000079457
mus_musculus	Faap100	ENSMUSG00000025384
rattus_norvegicus	Faap100	ENSRNOG00000036699

Protein

Protein identifiers

Fanconi anemia core complex-associated protein 100 — Q0VG06 (reviewed: Q0VG06)

Alternative names: Fanconi anemia-associated protein of 100 kDa

All UniProt accessions (7): Q0VG06, E7EVV8, F5GZS4, F5H095, F5H5G6, I3L2L9, J3KQD8

UniProt curated annotations — full annotation on UniProt →

Function. Plays a role in Fanconi anemia-associated DNA damage response network. Regulates FANCD2 monoubiquitination and the stability of the FA core complex. Induces chromosomal instability as well as hypersensitivity to DNA cross-linking agents, when repressed.

Subunit / interactions. Belongs to the multisubunit FA complex composed of FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL/PHF9, FANCM, FAAP24 and FAAP100. Forms a subcomplex with FANCB and FANCL.

Subcellular location. Nucleus.

Disease relevance. Fanconi anemia, complementation group X (FANCX) [MIM:621258] A form of Fanconi anemia, a disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair. FANCX is an autosomal recessive form characterized by multiple pregnancy losses and offspring presenting with severe developmental and hematologic abnormalities leading to death in utero or in early life. The disease is caused by variants affecting the gene represented in this entry.

Isoforms (3)

UniProt ID	Names	Canonical?
Q0VG06-1	1, b	yes
Q0VG06-2	2
Q0VG06-3	3, a

RefSeq proteins (1): NP_079437* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR029251	Faap100	Family

Pfam: PF15146

UniProt features (11 total): sequence variant 4, splice variant 3, chain 1, region of interest 1, sequence conflict 1, modified residue 1

Structure

Experimental structures (PDB)

6 structures.

PDB	Method	Resolution (Å)
7KZP	ELECTRON MICROSCOPY	3.1
7KZS	ELECTRON MICROSCOPY	4.2
7KZT	ELECTRON MICROSCOPY	4.2
7KZV	ELECTRON MICROSCOPY	4.2
7KZQ	ELECTRON MICROSCOPY	4.3
7KZR	ELECTRON MICROSCOPY	4.4

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q0VG06-F1	74.47	0.15

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 667

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-6783310	Fanconi Anemia Pathway
R-HSA-9833482	PKR-mediated signaling

MSigDB gene sets: 299 (showing top): PID_FANCONI_PATHWAY, GSE45365_HEALTHY_VS_MCMV_INFECTION_CD8_TCELL_IFNAR_KO_DN, TGGTGCT_MIR29A_MIR29B_MIR29C, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, CAGCTG_AP4_Q5, AML_Q6, GOBP_DNA_DAMAGE_RESPONSE, GOBP_INTERSTRAND_CROSS_LINK_REPAIR, REACTOME_FANCONI_ANEMIA_PATHWAY, REACTOME_DNA_REPAIR, NIKOLSKY_BREAST_CANCER_17Q21_Q25_AMPLICON, NERF_Q2, WANG_PROSTATE_CANCER_ANDROGEN_INDEPENDENT, GOCC_FANCONI_ANAEMIA_NUCLEAR_COMPLEX, GOBP_DNA_METABOLIC_PROCESS

GO Biological Process (3): interstrand cross-link repair (GO:0036297), DNA repair (GO:0006281), DNA damage response (GO:0006974)

GO Molecular Function (2): DNA binding (GO:0003677), protein binding (GO:0005515)

GO Cellular Component (5): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytosol (GO:0005829), Fanconi anaemia nuclear complex (GO:0043240)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
DNA Repair	1
Antimicrobial mechanism of IFN-stimulated genes	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
DNA repair	1
DNA metabolic process	1
DNA damage response	1
cellular response to stress	1
nucleic acid binding	1
binding	1
chromosome	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cytoplasm	1
nuclear protein-containing complex	1

Protein interactions and networks

STRING

1192 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FAAP100	FANCB	Q8NB91	999
FAAP100	FANCL	Q9NW38	999
FAAP100	FANCA	O15360	998
FAAP100	FAAP24	Q9BTP7	998
FAAP100	FANCF	Q9NPI8	997
FAAP100	FANCG	O15287	997
FAAP100	FANCE	Q9HB96	996
FAAP100	FANCM	Q8IYD8	995
FAAP100	FANCC	Q00597	995
FAAP100	F6S8H2	F6S8H2	992
FAAP100	CENPS	Q8N2Z9	956
FAAP100	CENPX	A8MT69	950
FAAP100	FANCD2	Q9BXW9	907
FAAP100	UBE2T	Q9NPD8	875
FAAP100	FANCI	Q9NVI1	820

IntAct

122 interactions, top by confidence:

A	B	Type	Score
FANCG	FANCA	psi-mi:“MI:0914”(association)	0.960
FANCA	FANCG	psi-mi:“MI:0914”(association)	0.960
FANCA	FANCG	psi-mi:“MI:0403”(colocalization)	0.960
SGF29	NDC80	psi-mi:“MI:0914”(association)	0.840
KRT31	HGS	psi-mi:“MI:0914”(association)	0.780
KRT34	TXLNA	psi-mi:“MI:0914”(association)	0.670
FANCA	FAAP100	psi-mi:“MI:0914”(association)	0.660
FANCA	FAAP100	psi-mi:“MI:0915”(physical association)	0.660
FAAP100	FANCB	psi-mi:“MI:0915”(physical association)	0.560
CDK18	UBL4A	psi-mi:“MI:0914”(association)	0.530
GPHA2	PLXNA2	psi-mi:“MI:0914”(association)	0.530
DEUP1	HIP1	psi-mi:“MI:0914”(association)	0.530
TSKS	RGPD8	psi-mi:“MI:0914”(association)	0.530
GGA1	CLCN3	psi-mi:“MI:0914”(association)	0.530
UBE2T	FAAP100	psi-mi:“MI:0914”(association)	0.530
GRK7	HSP90AA1	psi-mi:“MI:0914”(association)	0.530
RASSF8	CORO1A	psi-mi:“MI:0914”(association)	0.530
SYNGAP1	YWHAE	psi-mi:“MI:0914”(association)	0.530
NHSL3	NCK2	psi-mi:“MI:0914”(association)	0.530
SKA2	VSIG8	psi-mi:“MI:0914”(association)	0.530
CYCS	FAAP100	psi-mi:“MI:0914”(association)	0.530
LAGE3	CTSA	psi-mi:“MI:0914”(association)	0.530
LURAP1	TRIM24	psi-mi:“MI:0914”(association)	0.530
SGF29	MATN2	psi-mi:“MI:0914”(association)	0.530

BioGRID (160): C17orf70 (Affinity Capture-MS), C17orf70 (Affinity Capture-Western), C17orf70 (Affinity Capture-Western), C17orf70 (Affinity Capture-MS), C17orf70 (Two-hybrid), C17orf70 (Affinity Capture-Western), FANCM (Affinity Capture-MS), BLM (Affinity Capture-MS), FANCA (Affinity Capture-MS), TOP3A (Affinity Capture-MS), FANCB (Affinity Capture-MS), RMI1 (Affinity Capture-MS), FANCC (Affinity Capture-MS), FANCG (Affinity Capture-MS), FANCE (Affinity Capture-MS)

ESM2 similar proteins: A0JN53, A2ACJ2, D2I4M3, D4ACE5, E9Q2M9, G3HQ82, O15360, O75161, P59240, Q0VG06, Q1T7C0, Q24JP3, Q3KNJ2, Q3U5Q7, Q3U6Q4, Q3UK37, Q3ZAU7, Q400C9, Q400G9, Q571B6, Q5F479, Q5SW28, Q5UE93, Q6AYI4, Q6PJG6, Q6ZS81, Q7Z412, Q8BGI5, Q8BVF9, Q8C0R7, Q8C3R1, Q8C3S2, Q8CC12, Q8CEC0, Q8IWY9, Q8IXR5, Q8TC57, Q8TE82, Q8TF30, Q8WXE1

Diamond homologs: A2ACJ2, Q0VG06

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
FAAP100	“form complex”	“Fanconi anemia core complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 160 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Fanconi Anemia Pathway	5	14.1×	7e-03
Formation of the cornified envelope	9	8.0×	1e-03

GO biological processes:

GO term	Partners	Fold	FDR
morphogenesis of an epithelium	7	17.3×	6e-05
intermediate filament organization	9	15.6×	5e-06
epithelial cell differentiation	8	10.1×	4e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

177 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	3
Likely pathogenic	1
Uncertain significance	146
Likely benign	13
Benign	2

Top pathogenic / likely-pathogenic (4)

Variant ID	HGVS	Classification
3910000	NM_025161.6(FAAP100):c.1151_1161del (p.Glu384fs)	Pathogenic
3910001	NM_025161.6(FAAP100):c.2590C>T (p.Gln864Ter)	Pathogenic
3910002	NM_025161.6(FAAP100):c.1624A>C (p.Thr542Pro)	Pathogenic
4531686	NM_025161.6(FAAP100):c.2311-1G>A	Likely pathogenic

SpliceAI

1968 predictions. Top by Δscore:

Variant	Effect	Δscore
17:81540951:C:CC	acceptor_gain	1.0000
17:81541306:CA:C	donor_loss	1.0000
17:81541307:A:AC	donor_gain	1.0000
17:81541307:ACC:A	donor_loss	1.0000
17:81541307:ACCT:A	donor_gain	1.0000
17:81541308:C:CC	donor_gain	1.0000
17:81541308:CCT:C	donor_gain	1.0000
17:81541308:CCTC:C	donor_gain	1.0000
17:81541391:ATCGT:A	acceptor_gain	1.0000
17:81541392:TCGT:T	acceptor_gain	1.0000
17:81541393:CGT:C	acceptor_gain	1.0000
17:81541393:CGTC:C	acceptor_gain	1.0000
17:81541394:GT:G	acceptor_gain	1.0000
17:81541395:TCTG:T	acceptor_loss	1.0000
17:81541396:C:CC	acceptor_gain	1.0000
17:81541396:C:CG	acceptor_loss	1.0000
17:81543999:CATA:C	donor_loss	1.0000
17:81544000:ATACC:A	donor_loss	1.0000
17:81544001:TA:T	donor_loss	1.0000
17:81549201:CTCA:C	donor_loss	1.0000
17:81549203:CAC:C	donor_loss	1.0000
17:81549204:ACCT:A	donor_loss	1.0000
17:81549205:CCT:C	donor_gain	1.0000
17:81549359:CCAC:C	acceptor_gain	1.0000
17:81549360:CAC:C	acceptor_gain	1.0000
17:81549360:CACC:C	acceptor_gain	1.0000
17:81549364:T:C	acceptor_loss	1.0000
17:81552164:A:AC	donor_gain	1.0000
17:81552165:C:CC	donor_gain	1.0000
17:81552182:T:TA	donor_gain	1.0000

AlphaMissense

5626 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:81547461:A:G	W541R	0.994
17:81547461:A:T	W541R	0.994
17:81550751:C:A	G248V	0.992
17:81547603:G:C	S493R	0.990
17:81547603:G:T	S493R	0.990
17:81547605:T:G	S493R	0.990
17:81550819:G:C	F225L	0.986
17:81550819:G:T	F225L	0.986
17:81550821:A:G	F225L	0.986
17:81550411:G:C	S361R	0.984
17:81550411:G:T	S361R	0.984
17:81550413:T:G	S361R	0.984
17:81547459:C:A	W541C	0.983
17:81547459:C:G	W541C	0.983
17:81551095:G:C	F133L	0.983
17:81551095:G:T	F133L	0.983
17:81551097:A:G	F133L	0.983
17:81550807:A:C	F229L	0.982
17:81550807:A:T	F229L	0.982
17:81550809:A:G	F229L	0.982
17:81544058:G:C	S791R	0.980
17:81544058:G:T	S791R	0.980
17:81544060:T:G	S791R	0.980
17:81544071:A:G	I787T	0.980
17:81550751:C:T	G248D	0.980
17:81550745:A:G	L250P	0.979
17:81547625:A:G	L486P	0.978
17:81550649:A:T	V282D	0.977
17:81547489:G:C	N531K	0.975
17:81547489:G:T	N531K	0.975

dbSNP variants (sampled 300 via entrez): RS1000196594 (17:81541601 C>A), RS1000423652 (17:81545647 G>GCC), RS1000781854 (17:81554588 T>A,C), RS1000929161 (17:81540029 C>G,T), RS1001020692 (17:81548346 G>T), RS1001026999 (17:81544661 C>T), RS1001217800 (17:81546148 GGGACCT>G), RS1001398303 (17:81542140 C>T), RS1001414641 (17:81553373 G>A), RS1001742754 (17:81553767 A>G), RS1001764327 (17:81541872 T>C), RS1001949984 (17:81554848 C>A), RS1002153818 (17:81549748 A>C), RS1002303164 (17:81545326 G>A), RS1002357462 (17:81541235 C>A,G,T)

Disease associations

OMIM: gene MIM:611301 | disease phenotypes: MIM:621258

GenCC curated gene-disease

Mondo (1): fanconi anemia, complementation group 10 (MONDO:0979241)

Orphanet (0):

HPO phenotypes

159 total (30 of 159 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000010	Recurrent urinary tract infections
HP:0000023	Inguinal hernia
HP:0000027	Azoospermia
HP:0000028	Cryptorchidism
HP:0000035	Abnormal testis morphology
HP:0000047	Hypospadias
HP:0000062	Ambiguous genitalia
HP:0000072	Hydroureter
HP:0000079	Abnormality of the urinary system
HP:0000083	Renal insufficiency
HP:0000086	Ectopic kidney
HP:0000122	Unilateral renal agenesis
HP:0000130	Abnormality of the uterus
HP:0000135	Hypogonadism
HP:0000175	Cleft palate
HP:0000218	High palate
HP:0000238	Hydrocephalus
HP:0000252	Microcephaly
HP:0000268	Dolichocephaly
HP:0000286	Epicanthus
HP:0000316	Hypertelorism
HP:0000324	Facial asymmetry
HP:0000340	Sloping forehead
HP:0000347	Micrognathia
HP:0000364	Hearing abnormality
HP:0000365	Hearing impairment
HP:0000377	Abnormal pinna morphology
HP:0000452	Choanal stenosis
HP:0000453	Choanal atresia

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

33 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	increases expression	2
Particulate Matter	increases abundance, affects cotreatment, increases expression, decreases expression	2
aristolochic acid I	decreases expression	1
GSK-J4	decreases expression	1
FR900359	decreases phosphorylation	1
dicrotophos	increases expression	1
bisphenol A	decreases methylation	1
sodium arsenite	increases expression	1
cobaltous chloride	decreases expression	1
zinc chromate	decreases expression, increases abundance	1
1-hydroxypyrene	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
chromium hexavalent ion	decreases expression, increases abundance	1
ICG 001	increases expression	1
jinfukang	increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Temozolomide	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Air Pollutants, Occupational	decreases expression	1
Ethanol	affects cotreatment, increases abundance, increases expression	1
Atrazine	decreases expression	1
Benzo(a)pyrene	increases methylation	1
Formaldehyde	decreases expression	1
Gasoline	increases abundance, increases expression, affects cotreatment	1
Lead	affects methylation	1
Polycyclic Aromatic Hydrocarbons	affects cotreatment, increases abundance, increases expression	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Tretinoin	decreases expression	1
Valproic Acid	increases methylation	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SG11	HAP1 C17orf70 (-) 1	Cancer cell line	Male
CVCL_SG12	HAP1 C17orf70 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.